艾塞那肽治疗2型糖尿病的临床观察

Clinical observation of exenatide in the treatment of type 2 diabetes

目的评价艾塞那肽治疗2型糖尿病的疗效。方法糖尿病住院患者20例(治疗组)给予二甲双胍联合艾塞那肽治疗。随机选择与治疗组同期住院,病程、年龄、空腹血糖(FBG)及餐后2 h血糖(PG2 h)、糖化血红蛋白(HbA1c)、体重指数(BMI)无显著差异的患者作为对照组,给予二甲双胍联合格列美脲治疗。比较治疗前后两组患者FBG,PG2 h,HbA1c,BMI,低血糖发生次数。结果两组治疗16周后FBG、PG2 h、HbA1c均较治疗前明显下降(P<0.05),但两组之间差异无统计学意义(P>0.05)。对照组治疗前后BMI差异无统计学意义,而治疗组治疗16周后BMI明显低于治疗前(P>0.05)。治疗组发生症状性低血糖及夜间低血糖次数均明显少于对照组(P<0.01)。结论艾塞那肽可有效控制血糖,并且能明显降低BMI和低血糖发生次数。

Objective To evaluate the clinical efficacy of exenatide in the treatment of type 2 diabetes.Methods Twenty patients with type 2 diabetes（treatment group） were given metformin and exenatide.Twenty patients with type 2 diabetes matched with treatment group in age,sex,fasting blood glucose（FBG）,2 h postprandial glucose（PG2h）,hemoglobin A1c（HbA1c）,body mass index（BMI） were chosen as control group,and were given metformin and glimepiride.The changes of FBG,PG2 h,HbA1c,BMI and the incidence of hypoglycemia were compared before and after treatment between two groups.Results At 16 week after treatment,FBG,PG2 h,HbA1c were significantly decreased in two groups（P0.05）,but the difference between two groups was not statistically significant（P0.05）.BMI had no statistical change after treatment for 16 weeks in control group,but significantly decreased in treatment group（P0.05）.The incidences of symptomatic hypoglycemia and nocturnal hypoglycemia were significantly lower in treatment group than in control group（P0.01）.Conclusion Exenatide can effectively control the blood glucose,and significantly reduce BMI and incidence of hypoglycemia.